“Medical Unaudited (In millions) Three Months Ended March 31, 2026 Three Months Ended March 31, 2025 Revenues $ 72.1 $ 68.6 Income from operations $ 7.8 $ 6.7 Income from operations as a % of revenues 10.8 % 9.8 % 49 Table of Content s Medical segment revenues…”10-Q · Apr 29, 2026 ↗
Mirion Technologies, Inc.
MIR
Market read
Mirion Technologies, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- MIR's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if MIR's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- MIR's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +7.5% year over year.
- Operating margin changed +2.7 percentage points in the latest annual period.
- Net margin changed +7.3 percentage points in the latest annual period.
- Operating cash flow covered net income at 4.98x in the latest annual period.
- Foreign exchange has repeated favorable evidence across 4 filings.
- Macroeconomic conditions has repeated favorable evidence across 4 filings.
- Pricing and mix has repeated favorable evidence across 4 filings.
- Diluted shares increased 27.4% in the latest annual period.
- EV/sales is 83% below the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
15.84Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“This agreement was fully executed in March 2026 after the obtainment of customary performance guarantees (which had been previously delayed due to certain Russian sanctions).”10-Q · Apr 29, 2026 ↗
“The increase was primarily driven by foreign exchange impacts of $3.2 million, unfavorable margin mix of $2.9 million, inflation of $2.1 million, and costs associated with the recent acquisitions of $22.5 million.”10-Q · Apr 29, 2026 ↗
“Medical Unaudited (In millions) Three Months Ended March 31, 2026 Three Months Ended March 31, 2025 Revenues $ 72.1 $ 68.6 Income from operations $ 7.8 $ 6.7 Income from operations as a % of revenues 10.8 % 9.8 % 49 Table of Content s Medical segment revenues…”10-Q · Apr 29, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 4.5× · EV/sales 4.5×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for MIR. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for MIR. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind MIR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMEAMETEK, Inc.competitorFeb 19, 2026 ▾
“We believe the primary competitors in each of our segments are as follows: • Nuclear & Safety: Thermo Fisher Scientific, Curtiss-Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Caen System, Fluke (Fortive), Berthold Technologies and Framatome…”
FTVFortive CorporationcompetitorFeb 19, 2026 ▾
“We believe the primary competitors in each of our segments are as follows: • Nuclear & Safety: Thermo Fisher Scientific, Curtiss-Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Caen System, Fluke (Fortive), Berthold Technologies and Framatome…”
Depended on by
SMRNuScale Power CorporationsupplierFeb 26, 2026 ▾
“Other key suppliers include Framatome (fuel assemblies), Honeywell International Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MIR is currently a Leader in the organic co-movement group Radiation Detection & Safety. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for MIR; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.